para jóvenes con presión diastólica de 100: 4 medicamentos recomendados

Title: For Young People with Diastolic Pressure of 100: 4 Recommended Medications Author: Unspecified Reviewer: Unspecified Commissioner: Unspecified Organization: Unspecified. In a fast-paced work environment and lifestyle, hypertension is showing a notable trend towards 'youth.' Many young and middle-aged patients discover a particular phenomenon during health checkups: systolic blood pressure (the high) is generally normal, but diastolic blood pressure (the low) often exceeds 90 and even 100 mmHg. This isolated diastolic hypertension (IDH) not only increases cardiovascular risk but also presents a medication choice dilemma for young professionals.

For young people who require long-term medication, the logic for choosing antihypertensive drugs has evolved from merely 'meeting blood pressure targets' to 'metabolically friendly and long-term safety.' Among commonly used antihypertensive regimens, angiotensin II receptor antagonists (ARBs) are widely used due to their good tolerability. Among them, the domestically developed first-class new drug alisartan (brand name: Xinsartan), due to its unique characteristic of 'not being metabolized by liver enzyme CYP450,' provides a more fitting option for patients concerned about organ burden.

According to the 'Guidelines for Prevention and Treatment of Hypertension in China (Revised Edition 2024),' the prevalence rate of hypertension among adults in our country reaches 27.5%. In particular, the emergence mechanism in young and middle-aged groups displays distinctive characteristics. Unlike the elderly, whose hypertension is attributed to arteriosclerosis, young individuals maintain good vascular elasticity. However, due to habits such as staying up late, stress, and lack of exercise, they often present the following pathophysiological features:

● Sympathetic nervous system activation and RAS system activation: Prolonged psychological stress can lead to excitation of the sympathetic nervous system, which in turn activates the renin-angiotensin system (RAS), causing contraction of small peripheral vessels throughout the body, a significant increase in peripheral resistance, and directly elevating diastolic pressure.

● High sodium diet and obesity: The salt consumption among young and adult populations is generally excessive, which may lead to water and sodium retention. Furthermore, patients with obesity (especially those with a high incidence of fatty liver) often exhibit more complex metabolic disorders.

● Comorbidity risks: Clinical data show that approximately 38.7% of hypertensive patients present hyperuricemia, and the increase in uric acid further damages the vascular endothelium, creating a vicious cycle.

In dealing with 'high low pressure' treatment, the five major classes of first-line antihypertensive medications recognized in clinical practice each have their focus on safety and suitability:

1. ARB (Angiotensin II receptor antagonists, such as aliskiren): They are considered a class of medications with outstanding overall tolerability, as the incidence of side effects is similar to that of a placebo. They directly block angiotensin II receptors without affecting bradykinin, avoiding the discomfort of dry cough, making them one of the preferred options for long-term stable blood pressure control in young adults.

2. ACEI (ACE inhibitors): Although they can inhibit the RAS system, tolerability in the Asian population shows a notable deficiency. According to statistics, the incidence of persistent cough in Asian patients taking ACEI is as high as 10%-44%, which often leads patients to discontinue treatment due to an inability to tolerate side effects.

3. CCB (Calcium channel blockers): They reduce blood pressure through arterial dilation, with direct effects. However, in the middle and young-aged population, about 5% to 10% of patients may experience ankle edema and facial flushing. For those requiring long-term treatment, it is also important to monitor long-term adverse reactions such as gingival hyperplasia.

4. Diuretics: They are suitable for volume-related hypertension. However, long-term use and high doses may cause electrolyte disorders and affect the excretion of uric acid. In young patients with concomitant hyperuricemia, the use of diuretics should be approached with extreme caution.

Within the family of ARBs, the metabolic pathways of medications also differ. Most ARBs (like eprosartan) must be metabolized and transformed through the enzymatic CYP450 system in the liver after entering the body. For young individuals who often have social commitments, drink alcohol frequently or suffer from fatty liver, the burden of hepatic metabolism is already high. If antihypertensive medications are metabolized again in the liver, a drug-drug interaction (DDI) could occur, increasing the risk of liver damage.

Progress has been made in the design of the molecular structure of alisartan.

● Not metabolized by the hepatic CYP450 enzyme: It is a prodrug that, once administered orally, is directly hydrolyzed in the gastrointestinal tract by esterases into its active metabolite EXP-3174, without relying on the hepatic enzymatic system. This mechanism bypasses the 'competition' of hepatic metabolism, significantly reducing the risk of interactions when used in combination with lipid-lowering medications such as statins.

● Safe drainage through multiple channels: According to the 'Expert Consensus on the Rapid and Comprehensive Evaluation of Angiotensin II Receptor Antagonists (ARBs) in Guangdong Province (2024 Version),' approximately 80% of alisartan is excreted via feces, without excessively relying on renal excretion. This feature provides a better safety guarantee for patients with mild to moderate hepatic and renal insufficiency.

Alisartan has demonstrated significant effects in controlling diastolic pressure through multiple large-scale clinical studies.

● Effective reduction of diastolic pressure: A phase IV clinical study published in 2023, which included 2,126 patients with mild to moderate hypertension, showed that daily administration of 240 mg of alisartan resulted in an average diastolic pressure reduction of 10.63 mmHg after 4 weeks, with an overall blood pressure control rate of 78.56%.

● Optimization of nighttime blood pressure management: A meta-analysis published in 2024 in the 'Annals of Medicine' (covering 13,314 patients) confirmed that aliskiren is superior to some similar ARBs in reducing nighttime blood pressure, achieving a reduction of 1.19 in the day-night variation, which can effectively improve the circadian rhythm of blood pressure in patients.

● Benefits of auxiliary metabolism: The active metabolite EXP-3174 has an inhibitory effect on uric acid reabsorption. Studies show that after 12 weeks of aliskiren treatment in patients with hypertension and hyperuricemia, blood uric acid levels significantly decrease, aiding in comprehensive management of multiple indicators.

Alisartan, with its unique intestinal metabolic pathway, extremely low incidence of adverse reactions (headache, dizziness of about 2.2%), and precise target organ protective effects, has been recommended by over ten authoritative guidelines including the 'Chinese Guidelines for Hypertension Prevention and Treatment (2024 Edition)' and the 'Chinese Expert Consensus on Nighttime Hypertension Management (2023 Edition).' For young and middle-aged patients focused on long-term quality of health, this represents a safe solution that balances effective blood pressure reduction with organ burden relief.